

Alessandra Mangia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3640894/publications.pdf>

Version: 2024-02-01

265
papers

18,212
citations

26630

56
h-index

12946

131
g-index

279
all docs

279
docs citations

279
times ranked

13021
citing authors

#	ARTICLE	IF	CITATIONS
1	Boceprevir for Untreated Chronic HCV Genotype 1 Infection. New England Journal of Medicine, 2011, 364, 1195-1206.	27.0	2,352
2	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. New England Journal of Medicine, 2013, 368, 1878-1887.	27.0	1,605
3	Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. New England Journal of Medicine, 2014, 370, 1889-1898.	27.0	1,580
4	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. New England Journal of Medicine, 2015, 373, 2599-2607.	27.0	945
5	Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. New England Journal of Medicine, 2014, 370, 1993-2001.	27.0	752
6	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. New England Journal of Medicine, 2015, 373, 2608-2617.	27.0	740
7	Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3. New England Journal of Medicine, 2005, 352, 2609-2617.	27.0	672
8	Sustained virological response to interferon- α is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology, 2007, 45, 579-587.	7.3	585
9	Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. Gastroenterology, 2006, 130, 1636-1642.	1.3	517
10	An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response. Gastroenterology, 2010, 139, 821-827.e1.	1.3	285
11	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. New England Journal of Medicine, 2021, 385, 1547-1558.	27.0	284
12	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology, 2015, 62, 79-86.	7.3	232
13	Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology, 2008, 47, 43-50.	7.3	225
14	The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology, 2007, 45, 1164-1171.	7.3	214
15	Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointestinal Endoscopy, 2000, 51, 1-7.	1.0	199
16	Prophylaxis and treatment of hepatitis B in immunocompromised patients. Digestive and Liver Disease, 2007, 39, 397-408.	0.9	197
17	NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. Journal of Hepatology, 2017, 66, 910-918.	3.7	192
18	Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts. Annals of Internal Medicine, 2013, 158, 235.	3.9	187

#	ARTICLE	IF	CITATIONS
19	Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. <i>Hepatology</i> , 2013, 58, 65-72.	7.3	159
20	Interferon-Î» rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015, 6, 6422.	12.8	156
21	An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. <i>Journal of Hepatology</i> , 2005, 42, 744-751.	3.7	155
22	SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2009, 49, 1821-1827.	7.3	151
23	Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3729-3734.	3.9	146
24	Noninvasive Diagnosis of NAFLD and NASH. <i>Cells</i> , 2020, 9, 1005.	4.1	145
25	Hepatitis C pharmacogenetics: State of the art in 2010. <i>Hepatology</i> , 2011, 53, 336-345.	7.3	131
26	TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)ide Analogues. <i>Gastroenterology</i> , 2018, 154, 1764-1777.e7.	1.3	123
27	HCV and diabetes mellitus: evidence for a negative association. <i>American Journal of Gastroenterology</i> , 1998, 93, 2363-2367.	0.4	118
28	Reduced IFNÎ»4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. <i>Nature Communications</i> , 2014, 5, 5699.	12.8	117
29	HLA class II favors clearance of HCV infection and progression of the chronic liver damage. <i>Journal of Hepatology</i> , 1999, 30, 984-989.	3.7	113
30	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1202-1216.	3.7	111
31	Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 397-404.	3.7	104
32	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016, 7, 12757.	12.8	104
33	Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. <i>Gastroenterology</i> , 2019, 157, 227-241.e7.	1.3	99
34	High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHECY cohort confirm results from randomized clinical trials. <i>Hepatology</i> , 2012, 56, 2039-2050.	7.3	92
35	IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. <i>Cytokine</i> , 2004, 25, 103-109.	3.2	90
36	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	5.8	87

#	ARTICLE	IF	CITATIONS
37	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	5.8	87
38	IFN- γ 3, not IFN- γ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017, 49, 795-800.	21.4	86
39	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017, 37, 514-528.	3.9	84
40	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.	7.3	83
41	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. <i>Hepatology</i> , 2015, 62, 25-30.	7.3	82
42	Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 745-751.	1.6	81
43	Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1479-1481.	5.8	81
44	Anticardiolipin Antibodies in Patients With Liver Disease. <i>American Journal of Gastroenterology</i> , 1999, 94, 2983-2987.	0.4	78
45	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. <i>Hepatology</i> , 2017, 65, 1840-1850.	7.3	74
46	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	3.7	73
47	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 421-430.e6.	4.4	72
48	Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. <i>Hepatology</i> , 2011, 53, 389-395.	7.3	67
49	Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. <i>Hepatology</i> , 2013, 57, 974-984.	7.3	67
50	Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. <i>Hepatology</i> , 2016, 63, 1112-1119.	7.3	67
51	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	3.9	66
52	Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , 2009, 49, 358-363.	7.3	64
53	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	3.7	64
54	Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR- α in Huh-7 cells. <i>Journal of General Virology</i> , 2010, 91, 1678-1686.	2.9	58

#	ARTICLE	IF	CITATIONS
55	Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future. <i>Hepatology</i> , 2011, 54, 789-800.	7.3	58
56	Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir. <i>Antiviral Therapy</i> , 2018, 23, 229-238.	1.0	57
57	Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. <i>Digestive and Liver Disease</i> , 2010, 42, 81-91.	0.9	56
58	Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. <i>Hepatology</i> , 2011, 54, 772-780.	7.3	56
59	O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. <i>Journal of Hepatology</i> , 2015, 62, S221.	3.7	56
60	Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1042-1048.	5.8	56
61	Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. <i>Genes and Immunity</i> , 2014, 15, 500-505.	4.1	55
62	Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases. <i>PLoS ONE</i> , 2015, 10, e0117420.	2.5	54
63	Phyto-liposomes as nanoshuttles for water-insoluble silybin-phospholipid complex. <i>International Journal of Pharmaceutics</i> , 2014, 471, 173-181.	5.2	50
64	A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. <i>Hepatology</i> , 2001, 33, 989-993.	7.3	48
65	BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005, 578, 395-405.	1.0	48
66	Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 769-774.	3.7	46
67	Clinical management of HCV carriers with normal aminotransferase levels. <i>Digestive and Liver Disease</i> , 2003, 35, 362-369.	0.9	45
68	A randomized controlled trial of pegylated interferon α 2a (40â€fKD) or interferon α 2a plus ribavirin and amantadine vs interferon α 2a and ribavirin in treatment-naïve patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2005, 12, 292-299.	2.0	45
69	Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists? [letter]. <i>Blood</i> , 1996, 88, 752-754.	1.4	43
70	HCV genotypes in patients with liver disease of different stages and severity. <i>Journal of Hepatology</i> , 1997, 26, 1173-1178.	3.7	43
71	Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α 2b for chronic hepatitis type C. <i>Journal of Hepatology</i> , 1997, 27, 56-62.	3.7	42
72	Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg. <i>Digestive Diseases and Sciences</i> , 1996, 41, 2447-2452.	2.3	41

#	ARTICLE	IF	CITATIONS
73	Chronic viral hepatitis: The histology report. Digestive and Liver Disease, 2011, 43, S331-S343.	0.9	41
74	Comparison of three algorithms of noninvasive markers of fibrosis in chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2012, 35, 92-104.	3.7	41
75	High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. International Journal of Cancer, 2011, 129, 536-545.	5.1	40
76	Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1 and 6 and compensated cirrhosis or advanced fibrosis. Liver International, 2018, 38, 443-450.	3.9	40
77	Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. Journal of Hepatology, 2004, 40, 478-483.	3.7	38
78	Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and <scp>HCV</scp> genotype 1 or 4 infection. Alimentary Pharmacology and Therapeutics, 2017, 46, 424-431.	3.7	38
79	Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. Journal of Hepatology, 2017, 67, 680-686.	3.7	37
80	Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. Leukemia, 1996, 10, 1209-13.	7.2	37
81	Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. American Journal of Gastroenterology, 2019, 114, 1636-1641.	0.4	36
82	IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 2014, 61, 235-241.	3.7	35
83	External Validation of Biochemical Indices for Noninvasive Evaluation of Liver Fibrosis in HCV Chronic Hepatitis. American Journal of Gastroenterology, 2005, 100, 868-873.	0.4	34
84	HLA and enteric antineuronal antibodies in patients with achalasia. Neurogastroenterology and Motility, 2006, 18, 520-525.	3.0	34
85	Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. Journal of Hepatology, 2013, 59, 221-228.	3.7	34
86	Tailoring the length of antiviral treatment for hepatitis C. Gut, 2010, 59, 1-5.	12.1	32
87	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Gastroenterology, 2019, 156, 1496-1507.e7.	1.3	32
88	Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica, 2021, 113, 170-184.	3.4	32
89	HCV chronic infection and CCR5-Δ32/Δ32. Gastroenterology, 2003, 124, 868-869.	1.3	30
90	The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver International, 2016, 36, 971-976.	3.9	30

#	ARTICLE	IF	CITATIONS
91	Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 1994, 43, 125-128.	5.0	29
92	Short-term treatment duration for HCV-2 and HCV-3 infected patients. <i>Digestive and Liver Disease</i> , 2006, 38, 741-748.	0.9	29
93	Hepatitis C virus chronic infection and oral lichen planus: an Italian case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 647-652.	1.6	28
94	Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects. <i>Clinica Chimica Acta</i> , 2021, 522, 144-151.	1.1	28
95	Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial. <i>Journal of Hepatology</i> , 2001, 34, 441-446.	3.7	27
96	Short-Term Therapy for Patients with Hepatitis C Virus Genotype 1 Infection. <i>Drugs</i> , 2006, 66, 1807-1815.	10.9	27
97	Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteins. <i>Liver International</i> , 2009, 29, 661-669.	3.9	27
98	Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. <i>Gut</i> , 2002, 51, 864-869.	12.1	26
99	Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. <i>Journal of Hepatology</i> , 2010, 53, 1000-1005.	3.7	26
100	Insulin resistance, steatosis and hepatitis C virus. <i>Hepatology International</i> , 2013, 7, 782-789.	4.2	26
101	Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies. <i>Digestive and Liver Disease</i> , 2014, 46, S179-S185.	0.9	26
102	Phytoliposome-Based Silibinin Delivery System as a Promising Strategy to Prevent Hepatitis C Virus Infection. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 770-780.	1.1	26
103	The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. <i>BioMed Research International</i> , 2015, 2015, 1-12.	1.9	25
104	SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. <i>PLoS ONE</i> , 2019, 14, e0215783.	2.5	24
105	Lack of hepatitis C virus replication intermediate RNA in diseased skin tissue of chronic hepatitis C patients. , 1999, 59, 277-280.		23
106	Cytokine profile evaluation in patients with hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 9261-9.	3.3	23
107	Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience. <i>Journal of Hepatology</i> , 2017, 66, 711-717.	3.7	22
108	High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. <i>Journal of Hepatology</i> , 2002, 37, 109-116.	3.7	21

#	ARTICLE	IF	CITATIONS
109	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	5.8	21
110	The Cytokine Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0134594.	2.5	21
111	Sofosbuvir and Velpatasvir for Patients with HCV Infection. <i>New England Journal of Medicine</i> , 2016, 374, 1687-1689.	27.0	20
112	AISF position paper on liver transplantation and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 860-868.	0.9	20
113	Use of experimental design for optimisation of the cold plasma ICP-MS determination of lithium, aluminum and iron in soft drinks and alcoholic beverages. <i>Rapid Communications in Mass Spectrometry</i> , 2003, 17, 251-256.	1.5	19
114	Treatment of patients with HCV infection with or without liver biopsy. <i>Journal of Viral Hepatitis</i> , 2004, 11, 536-542.	2.0	19
115	Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. <i>World Journal of Gastroenterology</i> , 2013, 19, 8924.	3.3	19
116	IL28B Cc-Genotype Association with Hla-Dqb1*0301 Allele Increases the Prediction of Spontaneous HCV RNA Clearance in Thalassaemic HCV-Infected Patients. <i>Antiviral Therapy</i> , 2011, 16, 1309-1316.	1.0	18
117	Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1966-1972.	0.4	17
118	Thymosin alpha α 1 with peginterferon alfa α 2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 52-59.	2.0	17
119	A <sc>STAT</sc>4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 564-573.	3.7	17
120	SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. <i>Cells</i> , 2019, 8, 313.	4.1	17
121	Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?. <i>World Journal of Clinical Cases</i> , 2020, 8, 5831-5834.	0.8	17
122	To biopsy or not to biopsy. <i>Hepatology</i> , 2001, 34, 438-438.	7.3	16
123	The use of molecular assays in the management of viral hepatitis. <i>Digestive and Liver Disease</i> , 2008, 40, 395-404.	0.9	16
124	Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	16
125	Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg α 2b and ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1346-1353.	3.7	15
126	Hepatitis C virus micro-elimination: Where do we stand?. <i>World Journal of Gastroenterology</i> , 2021, 27, 1728-1737.	3.3	15

#	ARTICLE	IF	CITATIONS
127	Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study. <i>Digestive and Liver Disease</i> , 2002, 34, 285-289.	0.9	14
128	What's new in HCV genotype 2 treatment. <i>Liver International</i> , 2012, 32, 135-140.	3.9	14
129	Novel approach to separation and identification of organometallic compounds in complex mixtures by means of particle beam liquid chromatography/mass spectrometry: the case of diphosphine-substituted selenido iron and ruthenium clusters. , 1998, 12, 225-230.		13
130	Hepatitis C Infection in Patients with Chronic Kidney Disease. <i>International Journal of Artificial Organs</i> , 2008, 31, 15-33.	1.4	13
131	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 739-750.	3.0	13
132	Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. <i>Journal of Hepatology</i> , 2018, 68, S67-S68.	3.7	12
133	Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers. <i>Vaccines</i> , 2021, 9, 913.	4.4	12
134	Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose. <i>Frontiers in Public Health</i> , 2022, 10, 847384.	2.7	12
135	Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients. <i>Liver International</i> , 2011, 31, 36-41.	3.9	11
136	IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naïve patients with chronic HCV genotype 1 infection: the international observational Gen-C study. <i>SpringerPlus</i> , 2016, 5, 1990.	1.2	11
137	GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , 2019, 70, e2-e3.	3.7	11
138	Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 2019-2026.	2.3	11
139	Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 331-337.	3.7	10
140	Progress in promising anti-fibrotic therapies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1145-1152.	3.0	10
141	Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7144.	2.6	10
142	Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 438-446.	4.4	10
143	Short-duration therapy for hepatitis C: suitable for all?. <i>Journal of Viral Hepatitis</i> , 2007, 14, 221-227.	2.0	9
144	5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG + RIBAVIRIN IN TREATMENT-NAÏVE GT2/3 HCV-INFECTED PATIENTS (FISSION). <i>Journal of Hepatology</i> , 2013, 58, S3.	3.7	9

#	ARTICLE	IF	CITATIONS
145	P1112 LONG TERM FOLLOW-UP OF PATIENTS TREATED WITH SOFOSBUVIR IN THE FISSION, POSITRON, FUSION AND NEUTRINO PHASE 3 STUDIES. <i>Journal of Hepatology</i> , 2014, 60, S449.	3.7	9
146	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24.	0.9	9
147	Undetectable <sc>HCV</sc>â€<sc>RNA</sc> at treatmentâ€week 8 results in highâ€sustained virological response in <sc>HCV</sc> G1 treatmentâ€experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015, 22, 469-480.	2.0	9
148	Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. <i>BMC Gastroenterology</i> , 2020, 20, 251.	2.0	9
149	1331 LACK OF ASSOCIATION BETWEEN IL28B VARIANTS AND HBSAG CLEARANCE AFTER INTERFERON TREATMENT. <i>Journal of Hepatology</i> , 2011, 54, S525.	3.7	8
150	Treatment of Non-Genotype 1 Hepatitis C Virus Patients. <i>Current Gastroenterology Reports</i> , 2012, 14, 87-93.	2.5	8
151	Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era. <i>Digestive and Liver Disease</i> , 2013, 45, 356-361.	0.9	8
152	Prevalence and Clinical Importance of Hepatitis C Virus Genotype 2 K/1B Chimeras. <i>Journal of Hepatology</i> , 2016, 64, S136.	3.7	8
153	TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2017, 153, 1448-1449.	1.3	8
154	Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 772-778.	2.1	8
155	Associations between Allelic Variants of the Human IgH 3â€2 Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2021, 9, 1207.	4.4	8
156	Gallbladder Emptying in Patients with Primary Achalasia. <i>Digestion</i> , 1992, 52, 152-156.	2.3	7
157	Development of a multigenic plasmid vector for HCV DNA immunization. <i>Research in Virology</i> , 1998, 149, 315-319.	0.7	7
158	Clinical Significance of the CCR5delta32 Allele in Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e106424.	2.5	7
159	Combined GS-4774 and tenofovir therapy can improve HBV-specific T cell responses in patients with chronic active hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, S29.	3.7	7
160	Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis. <i>PLoS ONE</i> , 2018, 13, e0200568.	2.5	7
161	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-Î²1 dependent mechanisms. <i>Scientific Reports</i> , 2019, 9, 1439.	3.3	7
162	Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patientâ€centered program from Italy. <i>United European Gastroenterology Journal</i> , 2021, 9, 1109.	3.8	7

#	ARTICLE	IF	CITATIONS
163	Sofosbuvir+velpatasvir+voxilaprevir in adolescents 12 to 17 years old with HCV infection. <i>Hepatology</i> , 2022, 76, 445-455.	7.3	7
164	93 HCV genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled study. <i>Journal of Hepatology</i> , 2004, 40, 34.	3.7	6
165	Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus. <i>Journal of Medical Economics</i> , 2008, 11, 151-163.	2.1	6
166	Early discontinuation of ribavirin in HCVâ€2 and HCVâ€3 patients responding to Pegâ€interferon alfaâ€2a and ribavirin. <i>Journal of Viral Hepatitis</i> , 2009, 16, 28-35.	2.0	6
167	IL28B: A new wager in the skyline of hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2011, 43, 177-179.	0.9	6
168	Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. <i>Scientific Reports</i> , 2017, 7, 15843.	3.3	6
169	Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 190-200.	1.5	6
170	Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 1924-1928.	0.4	6
171	Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. <i>Annals of Gastroenterology</i> , 2017, 30, 327-343.	0.6	6
172	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQâ€1. <i>American Journal of Human Genetics</i> , 2022, 109, 299-310.	6.2	6
173	Update on the Treatment of Patients With Nonâ€Genotype 1 Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2013, 56, 1294-1300.	5.8	5
174	Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. <i>PLoS ONE</i> , 2016, 11, e0151703.	2.5	5
175	THU-144-Ledipasvir/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis. <i>Journal of Hepatology</i> , 2019, 70, e225.	3.7	5
176	Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	5
177	A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 2090-2098.	4.0	5
178	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. <i>Genes and Immunity</i> , 2020, 21, 348-359.	4.1	5
179	High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55â€85. <i>Pathogens</i> , 2021, 10, 695.	2.8	5
180	Individualized Treatment of Genotype 1 NaÃve Patients: An Italian Multicenter Field Practice Experience. <i>PLoS ONE</i> , 2014, 9, e110284.	2.5	5

#	ARTICLE	IF	CITATIONS
181	Peginterferon Alfa-2b and Ribavirin for 12 versus 24 Weeks in HCV Infection. New England Journal of Medicine, 2005, 353, 1182-1183.	27.0	4
182	[7] IN PTS WHO CLEAR HCVRNA AT WEEK 12, SVR IS HIGHER AFTER 72 THAN AFTER 48 WEEKS TX: RESULTS OF A RANDOMIZED CONTROLLED TRIAL (RCT). Journal of Hepatology, 2007, 46, S6.	3.7	4
183	Short treatment to patients with genotype 2 or 3. Hepatology, 2008, 48, 694-694.	7.3	4
184	Treating fatty liver for the prevention of cardiovascular diseases. Hepatology, 2010, 52, 1174-1175.	7.3	4
185	1170 IL28B C/C POLYMORPHISM IS PREDICTIVE OF SPONTANEOUS HCV RNA CLEARANCE IN PATIENTS WITH THALASSEMIA MAJOR. Journal of Hepatology, 2010, 52, S452.	3.7	4
186	Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. Liver International, 2014, 34, e308-16.	3.9	4
187	Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. Liver International, 2015, 35, 482-488.	3.9	4
188	Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans. Hepatology, 2016, 64, 2264-2265.	7.3	4
189	Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways. Advances in Therapy, 2021, 38, 1397-1403.	2.9	4
190	Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy. BMC Infectious Diseases, 2022, 22, 3.	2.9	4
191	PEG-IFN alfa-2a (40kd) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naïve patients with chronic hepatitis C (CHC). Journal of Hepatology, 2003, 38, 146.	3.7	3
192	8 FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN COMBINATION. Journal of Hepatology, 2008, 48, S6.	3.7	3
193	756 LARGE-SCALE MULTICENTER COMPARISON OF THREE ALGORITHMS COMBINING SERUM NON-INVASIVE MARKERS FOR LIVER FIBROSIS IN CHRONIC HEPATITIS C. Journal of Hepatology, 2008, 48, S282.	3.7	3
194	O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY. Journal of Hepatology, 2014, 60, S523-S524.	3.7	3
195	Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. PLoS ONE, 2015, 10, e0138503.	2.5	3
196	P1332 : The astral studies: evaluation of SOF/GS-5816 single tablet regimen for the treatment of genotype 1 HCV infection. Journal of Hepatology, 2015, 62, S855-S856.	3.7	3
197	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transplant International, 2017, 30, 1253-1265.	1.6	3
198	Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multicentre study and systematic review. Journal of Viral Hepatitis, 2018, 25, 920-929.	2.0	3

#	ARTICLE	IF	CITATIONS
199	Inpatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. <i>Journal of Viral Hepatitis</i> , 2018, 25, 344-353.	2.0	3
200	Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy. <i>Medicine (United States)</i> , 2018, 97, e11307.	1.0	3
201	Thrombosis, recurrent abortions and intrauterine foetal death in a patient with lupus anticoagulant. <i>Clinical Rheumatology</i> , 1985, 4, 455-457.	2.2	2
202	Skin is not a site of HCV replication in lichen planus (LP). <i>Gastroenterology</i> , 1998, 114, A1295.	1.3	2
203	Re-treatment of interferon (IFN) plus ribavirin (RBV) nonresponders with peginterferon (PEG-IFN) Alfa-2A (40KD) (Pegasys) plus RBV and amantadine (AMA) or IFN Alfa-2A (Roferon-A) plus RBV and AMA. Interim results of a multicenter randomized study. <i>Journal of Hepatology</i> , 2003, 38, 129.	3.7	2
204	630 RIBAVIRIN (RBV) DOSAGE AS INDEPENDENT PREDICTOR OF RVR IN HCV GENOTYPE 2 (HCV-2) AND 3 (HCV-3) PATIENTS UNDERGOING COMBINED TREATMENT WITH PEG INTERFERON (PEG-IFN) ALPHA-2B. <i>Journal of Hepatology</i> , 2009, 50, S232.	3.7	2
205	126 PREDICTIVE ROLE OF IL28B C/C GENOTYPE ON SVR AND RVR IN PATIENTS WITH GENOTYPE 2/3 CHRONIC INFECTION. <i>Journal of Hepatology</i> , 2010, 52, S56-S57.	3.7	2
206	High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir/Velpatasvir (SOF/VEL) combination for 12 weeks without Ribavirin (RBV). <i>Journal of Hepatology</i> , 2018, 68, S273-S274.	3.7	2
207	Sofosbuvir + Ribavirin With or Without Peginterferon Is Well-Tolerated and Associated with High SVR Rates: Integrated Results from 4 Phase 3 Trials in HCV Genotype 1-6. <i>American Journal of Gastroenterology</i> , 2013, 108, S123.	0.4	2
208	Treatment Outcomes and Predictors of Response in Treatment-Naïve HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHECY Cohort. <i>Hepato-Gastroenterology</i> , 2014, 61, 1094-106.	0.5	2
209	Thromboxane production in diabetes mellitus. <i>Research in Clinic and Laboratory</i> , 1986, 16, 539-542.	0.3	2
210	Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV. <i>New England Journal of Medicine</i> , 2007, 357, 1660-1662.	27.0	1
211	Are HCV genotypes 2 and 3 the same or different?. <i>Current Hepatitis Reports</i> , 2008, 7, 88-92.	0.3	1
212	Reply.. <i>Hepatology</i> , 2008, 48, 1020-1021.	7.3	1
213	Management of patients with hepatitis C virus genotype 2 or 3: Comments on updated american association for the study of liver diseases practice guidelines. <i>Hepatology</i> , 2009, 50, 323-323.	7.3	1
214	Optimal dosage of ribavirin. <i>Hepatology</i> , 2010, 52, 1173-1174.	7.3	1
215	851 GENETIC PREDICTORS OF STEATOSIS AND FIBROSIS IN NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD). <i>Journal of Hepatology</i> , 2011, 54, S339-S340.	3.7	1
216	73 WORLDWIDE EXPERIENCE TREATING CHRONIC HEPATITIS C (CHC) WITH PEGINTERFERON ALFA/RIBAVIRIN: FINAL RESULTS FROM 7163 NAIVE, MONO-INFECTED PATIENTS ENROLLED IN THE LARGE MULTINATIONAL PROPHECY COHORT STUDY. <i>Journal of Hepatology</i> , 2012, 56, S32.	3.7	1

#	ARTICLE	IF	CITATIONS
217	1135 IL28B CC GENOTYPE IS ASSOCIATED WITH HIGHER ON-TREATMENT-RESPONSE RATES IN PTS WITH HCV-3: INTERIM RESULTS OF THE WRITE STUDY. Journal of Hepatology, 2012, 56, S448.	3.7	1
218	1085 PEG-INTERFERON AND RIBAVIRIN IN HCV-RELATED CIRRHOTIC PATIENTS WITH PROFOUND THROMBOCYTOPENIA. Journal of Hepatology, 2012, 56, S426-S427.	3.7	1
219	Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis. Journal of Hepatology, 2013, 58, 1259.	3.7	1
220	1171 EFFECTS OF A NEW LIPOSOME-ENCAPSULATED FORMULATION OF SILYBIN ON HEPATITIS C VIRUS INFECTION. Journal of Hepatology, 2013, 58, S476.	3.7	1
221	In routine clinical practice, few physicians use early viral kinetics to guide <scp>HCV</scp> dual therapy treatment decisions. Liver International, 2014, 34, e217-28.	3.9	1
222	75. Cytokine, 2014, 70, 45-46.	3.2	1
223	Efficacy and safety of Boceprevir-based therapy in HCV G1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey. Digestive and Liver Disease, 2014, 46, e12.	0.9	1
224	P1220 MODELING PREDICTS CLINICALLY MEANINGFUL SVR RATES IN GENOTYPE 1 TREATMENT-EXPERIENCED PATIENTS BASED ON RESULTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS TREATED WITH SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS. Journal of Hepatology, 2014, 60, S495.	3.7	1
225	Sustained Virological Responses (SVR) of 97% in Genotype 2 (GT-2) Patients with F3/4 Stage of Fibrosis Treated with Sofosbuvir (SOF) and Weight-Based Ribavirin (RBV): A Real Life, Single Centre Experience. Journal of Hepatology, 2016, 64, S246-S247.	3.7	1
226	On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1 HCV Infection Treated with Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the Astral-1, Astral-2, and Astral-3 Studies. Journal of Hepatology, 2016, 64, S817.	3.7	1
227	Mortality rate and predictors of liver disease damage in histologically diagnosed Nonalcoholic Steatohepatitis: a 15 years follow-up cohort study. Journal of Hepatology, 2017, 66, S148.	3.7	1
228	Predictors of sustained virological response 12 weeks after the end of treatment in hepatitis C virus GT3 infected patients receiving IFN-free antiviral treatments. Journal of Hepatology, 2017, 66, S281.	3.7	1
229	Dual proteotoxic stress accelerates liver injury via activation of <scp>p62</scp>. Journal of Pathology, 2021, 254, 80-91.	4.5	1
230	Real-world effectiveness of sofosbuvir/velpatasvir for the treatment of hepatitis C virus in prison settings. Future Virology, 0, .	1.8	1
231	Letter: now is the time to remove complexity from HCV guidelines to ensure that elimination remains a priority. Alimentary Pharmacology and Therapeutics, 2020, 52, 1096-1097.	3.7	1
232	Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus. European Review for Medical and Pharmacological Sciences, 2018, 22, 7024-7033.	0.7	1
233	Does genotype affect the course of HCV infection?. Gastroenterology, 1995, 108, A1117.	1.3	0
234	Hepatitis B virus (HBV) reinfection in liver transplant patientsreceiving hepatitis B immune globulin: Role of S mutants. Journal of Hepatology, 2000, 32, 44.	3.7	0

#	ARTICLE	IF	CITATIONS
235	Re-treatment with interferon plus ribavirin of chronic hepatitis C nonresponders to interferon monotherapy: A meta-analysis of individual patient data. <i>Digestive and Liver Disease</i> , 2001, 33, A60.	0.9	0
236	Monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy: multi-center evaluation of the INNO-LiPA HBV-DR. <i>Journal of Hepatology</i> , 2001, 34, 137.	3.7	0
237	A 3-ARM randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis. <i>Journal of Hepatology</i> , 2002, 36, 117.	3.7	0
238	IL-10 ATA haplotype and 1st interon IFN-gamma polymorphisms are more frequent in pts with spontaneous HCV clearance. <i>Journal of Hepatology</i> , 2002, 36, 117.	3.7	0
239	High SVR rate in HCV pts with normal or increased ALT: A controlled study with IFN alpha 2B and ribavirin. <i>Journal of Hepatology</i> , 2003, 38, 153.	3.7	0
240	A controlled trial on treatment of patients with HCV infection and abnormal liver function tests with or without liver biopsy. <i>Journal of Hepatology</i> , 2003, 38, 124.	3.7	0
241	Unusual sonographic appearance of a haemorrhagic biliary cyst. <i>European Journal of Radiology Extra</i> , 2005, 54, 103-105.	0.1	0
242	[436] THE HEPATITIS C VIRUS CORE PROTEIN OF GENOTYPES 3a AND 1b DOWN-REGULATES INSULIN RECEPTOR SUBSTRATE 1 VIA GENOTYPE-SPECIFIC MECHANISMS. <i>Journal of Hepatology</i> , 2007, 46, S166.	3.7	0
243	609 BASELINE CHARACTERISTICS AND WEEK-4 RESPONSE AMONG 1546 CHC PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 AND 4: INTERIM RESULTS OF THE PROPHEYS COHORT. <i>Journal of Hepatology</i> , 2009, 50, S224.	3.7	0
244	256 BASELINE CHARACTERISTICS AND ON-TREATMENT PREDICTORS OF RESPONSES FROM REAL-WORLD PATIENT COHORTS: INTERIM RESULTS OF THE MULTINATIONAL PROPHEYS COHORTS. <i>Journal of Hepatology</i> , 2010, 52, S108.	3.7	0
245	T-10 Effect of prevalence of fibrosis stages on the performance of non-invasive fibrosis biomarkers in chronic liver diseases (CLDs): Results of a large-scale, international study. <i>Digestive and Liver Disease</i> , 2011, 43, S80.	0.9	0
246	OC.10.5: THE EFFECT OF PREVALENCE OF LIVER FIBROSIS STAGES IN PERFORMANCE OF NONINVASIVE FIBROSIS BIOMARKERS IN CHRONIC LIVER DISEASES (CLDS): RESULTS OF AN INDEPENDENT, INTERNATIONAL STUDY. <i>Digestive and Liver Disease</i> , 2011, 43, S141.	0.9	0
247	1088 RATES AND PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE AND RELAPSE IN ITALIAN NAIVE MONO-INFECTED CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGINTERFERON ALFA/RIBAVIRIN: PROPHEYS 2 FINAL ANALYSIS. <i>Journal of Hepatology</i> , 2012, 56, S427-S428.	3.7	0
248	1134 PREMATURE TREATMENT DISCONTINUATION OF PEG-IFN α -2A/RBV DUE TO GOOD VIRAL RESPONSES AND INSUFFICIENT VIRAL RESPONSES AMONG HCV GENOTYPE 1, 2 AND 3 PATIENTS FROM PROPHEYS. <i>Journal of Hepatology</i> , 2012, 56, S447-S448.	3.7	0
249	815 FACTORS ASSOCIATED WITH INTOLERANCE TO PEGINTERFERON α /RIBAVIRIN IN TREATMENT-NAIVE, CIRRHOTIC/NON-CIRRHOTIC HCV GENOTYPE 1-INFECTED PATIENTS: ANALYSIS OF DATA FROM THE MULTINATIONAL PROPHEYS COHORTS. <i>Journal of Hepatology</i> , 2013, 58, S334.	3.7	0
250	790 HEPATITIS C TREATMENT OUTCOMES AND PREDICTORS OF RESPONSE IN TREATMENT-NAIVE PATIENTS TREATED WITH PEGINTERFERON α /RIBAVIRIN IN REAL-WORLD ITALIAN CLINICS COMPARED WITH OTHER COUNTRIES: PROPHEYS SUB-ANALYSIS. <i>Journal of Hepatology</i> , 2013, 58, S322.	3.7	0
251	P1126 IMPACT OF SAFETY-RELATED DOSE REDUCTIONS AND DISCONTINUATIONS (SR-RD) ON SUSTAINED VIROLOGICAL RESPONSE (SVR) IN TREATMENT-NAIVE CHRONIC HEPATITIS C PATIENTS RECEIVING PEGINTERFERON ALFA-2a/RIBAVIRIN: RESULTS FROM GUARD-C. <i>Journal of Hepatology</i> , 2014, 60, S455.	3.7	0
252	Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors. <i>Digestive and Liver Disease</i> , 2014, 46, e45.	0.9	0

#	ARTICLE	IF	CITATIONS
253	Reply to: “Built-in bias in HCV clearance in acute HCV infection”. Journal of Hepatology, 2014, 60, 461-463.	3.7	0
254	P1208 PREDICTION OF SEVERE CUTANEOUS REACTION DURING TRIPLE THERAPY IN HCV: VALIDATION OF A GWAS CANDIDATE GENETIC MARKER. Journal of Hepatology, 2014, 60, S490-S491.	3.7	0
255	P1167 rs12979860 IL28B GENOTYPE IS ASSOCIATED WITH ADVANCED FIBROSIS IN HCV GENOTYPE 1-INFECTED EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE INTERNATIONAL GEN-C STUDY. Journal of Hepatology, 2014, 60, S473.	3.7	0
256	P.17.11 HIGH RATES OF VIROLOGICAL RESPONSES WITH PEG-IFN AND RBV RE-TREATMENT FOLLOWING RELAPSE TO SOF+RBV. Digestive and Liver Disease, 2014, 46, S124.	0.9	0
257	P0858 : Early HCV RNA decline by baseline characteristics in HCV infected patients receiving sofosbuvir-based treatment: An Italian single center experience. Journal of Hepatology, 2015, 62, S662.	3.7	0
258	499 Ribavirin-Free Regimen With Velpatasvir and Sofosbuvir is Associated With High Efficiency and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From ASTRAL-2 and 3 Clinical Trials. Gastroenterology, 2016, 150, S1035.	1.3	0
259	751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin. Gastroenterology, 2016, 150, S1046.	1.3	0
260	Su1414 On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies. Gastroenterology, 2016, 150, S1092-S1093.	1.3	0
261	Editorial: good news to patients with thalassaemia “HCV” clearance made easy with direct acting antivirals. Authors’ reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 629-630.	3.7	0
262	Sustainable improvement of patient-reported outcomes in cirrhotic patients with hepatitis C who achieved sustained virologic response. Journal of Hepatology, 2018, 68, S530-S531.	3.7	0
263	The evolution of treatment for HCV Genotype 3 (GT3) infected patients with advanced fibrosis/cirrhosis over time. Journal of Hepatology, 2018, 68, S274.	3.7	0
264	THU-348-Patients with non-alcoholic steatohepatitis experience severe impairment of health related quality of life. Journal of Hepatology, 2019, 70, e313.	3.7	0
265	Current Management of Patients with HCV Genotype 2. , 2021, , 83-95.		0